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OBJECTIVES: Recombinant activated factor VIIa room temperature stable (rFVIIa 
RTS) enables immediate access to treatment, which may lead to more rapid bleeding 
control and require less product compared to original rFVIIa, leading to cost savings 
despite the greater cost of rFVIIa RTS. The total annual cost of managing mild/moder-
ate bleeds in one average hemophilia patient with high titre, high responding inhibitors 
by original rFVIIa and rFVIIa RTS was examined. METHODS: Only main medica-
tions costs were compared from the public payer perspective. Resource utilization and 
clinical outcomes were based on a review of international literature. Excel based 
budget impact model (BIM) was developed to assess the ﬁ nancial consequences of 
treating bleeding episodes with rFVIIa compared to current treatment practices. 
Cohort of individuals in BIM can be followed sequentially from bleed initiation, taking 
into consideration ﬁ rst-line efﬁ cacy, switching to other products, re-bleeds and bleed 
cessation. RESULTS: Patients with rFVIIa RTS were treated on an outpatient or home 
basis. First-line and second-line efﬁ cacy was assumed to be 92% for original rFVIIa 
and rFVIIa RTS. An early treatment with rFVIIa was associated with a lower incidence 
of re-bleeds compared to delayed treatment 5.2% vs. 13.7% and therefore with less 
product usage 2.1 vs. 2.3 doses per treatment line. Total annual costs per patient from 
initiation to cessation in the current treatment environment was CSD 12.58 million 
(c0.12 million). One-way sensitivity analyses showed that at price of rFVIIa RTS from 
0% to 16% premium introduction of this new form can deliver savings for the Serbian 
health care budget due to immediate patients’ access to the treatment. If not literature 
but current real life treatment patterns are considered savings can reach 56%. CON-
CLUSIONS: rFVIIa room temperature stable (RTS) in comparison to the original 
rFVIIa represents cost-saving ﬁ rst-line treatment option for the Serbian health care 
system.
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OBJECTIVES: The budget impact of treating patients with severe chronic cancer and 
non-cancer pain with OROS®hydromorphone once-daily was determined in the 
German health care system. METHODS: An existing Excel® based hypothetical 
budget impact model (Fleischmann et al. 2008) calculating the cost consequences of 
using strong opioids (WHO step III) was updated using new market data (2009) and 
current prices (2010 public prices). The model has a one year time horizon adopting 
the perspective of the social health insurance accounting for costs of opioids, break-
through pain and adverse events. Patient numbers are calculated using data from 
literature; adverse event rates are based on literature ﬁ ndings. Comparators included 
sustained-release morphine (twice-daily), controlled-release oxycodone (twice-daily), 
hydromorphone (twice-daily), transdermal fentanyl and transdermal buprenorphine. 
Initial prescription share of OROS® hydromorphone was 3.7% (2009). This share was 
hypothetically extended to 5%. It was assumed that this increase in prescription is 
gained by switching patients from their previous oral medication to OROS® hydro-
morphone. Titration and maintenance dosing schemes taken from previous analyses 
are used to model the switch. Morphine equivalences were chosen according to SmPC. 
RESULTS: The number of patients treated was estimated to be 810,608 per year. The 
model predicted that the expansion of OROS® HM would lower the per patient drug 
cost from c592.28 to c590.88. Due to generic entry drug cost per patient was consider-
ably lower than in the previous version of the model (c679.52). The model also 
predicts that if the prescription share of OROS® HM increased to 5% the total budget 
for strong opioids would decrease by c1,135,086. CONCLUSIONS: Our analysis 
suggests that under current circumstances our ﬁ nding from 2008 that extending the 
use of OROS® hydromorphone to treat patients with severe chronic pain will reduce 
the overall budget spent on strong opioids is still valid.
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OBJECTIVES: To assess the economic impact for the Spanish health care system of 
the substitution of Flebogamma by Privigen in the Spanish market setting for liquid 
intravenous immunoglobulins (IVIGs) in 2009. METHODS: A budget impact model 
was developed with analyses based on Spanish data on disease prevalence, population 
forecasts, drug use, health care resource utilization and market shares. Data was 
obtained by literature research and consulting a panel of local clinical experts. The 
perspective of the Spanish health care system was considered and a 5-year time horizon 
was evaluated. All costs referred to 2009 and a discount rate of 3% was applied. 
Indications of IVIGs included in this study were replacement therapy, immunomodula-
tion and allogeneic bone marrow transplantation. Sub-indications of these primary 
indications were also considered distinguishing between children and adolescents vs. 
adults. IGIV treatments considered were Kiovig, Octagamocta, Flebogamma and 
Privigen. Direct medical annual costs per patient for each (sub-)indication were esti-
mated before and after the substitution by Privigen. RESULTS: The target population 
for IVIG treatment was estimated to be 5743 in 2009, increasing to 6926 in 2014. 
Total costs for the next 5 years with the actual market share were estimated at c565 
million. a minimum increase in Privigen’s market share from 2% in the ﬁ rst year up 
to 12% in the ﬁ fth year- was considered. Under these circumstances, the estimated 
costs were c563c million which represents a saving of c2 million for the Spanish health 
care system. CONCLUSIONS: An increase of Privigen’s market share in Spain is likely 
to decrease the budget utilization of the health care system within the next 5 years. 
Savings are the result of less drug and administration costs per treated patient.
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OBJECTIVES: The use of strong opioid analgesics to treat severe chronic pain is 
associated with adverse events (AEs) and treatment discontinuations, which can 
increase the overall cost of treatment. New interventions with more favourable safety 
proﬁ les could reduce these costs. An economic model was constructed to investigate 
the potential budget savings associated with the introduction of an intervention with 
increased tolerability to a formulary. METHODS: A prevalence-based, deterministic 
budget impact model with a ﬁ ve-year time horizon was developed from the perspective 
of a UK health care budget-holder. The model takes into account drug acquisition, 
AE and discontinuation costs associated with the ﬁ ve most frequently-used strong 
opioid analgesics (WHO step 3) in the UK. Cost and usage data were derived from 
the British National Formulary, market research studies and physician interviews. AE 
and discontinuation rates were derived from published studies. RESULTS: In a theo-
retical population of 100,000 individuals, the model estimated that 205 patients 
experienced severe chronic pain and subsequently received strong opioid analgesics. 
The overall annual cost of treating these patients with currently-available strong 
opioid analgesics was estimated to be £152,426, 62% of which was spent managing 
AEs and discontinuations. Over ﬁ ve years, the model showed that if 50% of patients 
received an alternative strong analgesic which reduces the number of AEs and discon-
tinuations by 25% (compared to currently-used strong opioid analgesics), there would 
be 198 fewer AEs and 58 fewer discontinuations. This would result in a cost saving 
of £51,985. CONCLUSIONS: The cost of managing AEs and discontinuations is a 
signiﬁ cant contributor to the overall treatment cost associated with strong opioid 
analgesics. New treatments with improved safety proﬁ les may reduce the economic 
burden of managing AEs and discontinuations associated with the use of strong opioid 
analgesics. This may partially or even completely offset any potential increase in 
acquisition costs.
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OBJECTIVES: MDS is a rare hematological disease, that affects the production of 
blood cells. One of the goals of the treatment is to maintain the blood-cell count in 
near-normal levels. The means to achieve this are done mainly with the use of hema-
topoietic- growth factors and transfusions. Our objective was to determine the costs 
of this supportive treatment under the private payers perspective in Brazil, for patients 
with intermediate risk (INT) MDS. METHODS: We adapted the National Compre-
hensive Cancer Network (NCCN) for INT MDS decision tree to the reality of the 
Health care system in Brazil. Then, we calculated the costs for each branch of the tree, 
according to the local prices. We also simulated the total costs for a cohort of 100 
patients, distributed in the branches according to the expected epidemiology. We 
assumed an horizon of one year of treatment. RESULTS: The mean cost of SC for 
MDS was US$45,006/ patient/ year. This value can vary from US$33,368 to 
US$104,210, according to the patients’ characteristics and types of treatments used. 
Overall, patients requiring the use of immunotherapy, with anti-tymocyte globulins 
were associated with the highest costs. Those achieving disease stabilization solely 
with the use of erythropoietin were associated with the lowest costs. CONCLUSIONS: 
The SC of SMD is associated with a mean cost of US$45,000/patient/year in Brazil. 
New treatments have the potential to change this scenario if they can diminish the 
requirements for the costliest supportive procedures.
